Publications

library
The following papers and articles have been published by the ReDO team and its associates:

The Repurposing Drugs in Oncology (ReDO) Project : A paper that introduces the ReDO project and explains our rationale, aims and the science that underlies our thinking. [Published July 10th 2014]

Mebendazole as an anti-cancer agent : A review of the evidence for an anticancer effect of the generic anti-parasitic drug mebendazole. Includes a discussion of potential combinations with other drugs for treating specific types of cancer. [Published July 10th 2014]

Recycling existing drugs for cancer therapy: delivering low cost cancer care : An editorial from the journal ecancermedicalscience on the case for drug repurposing for cancer. [Published July 10th 2014]

Cimetidine as an anti-cancer agent : A review of the evidence for an anticancer effect of the generic and well-known antacid cimetidine. Includes a discussion of potential combinations with other drugs for treating specific types of cancer. [Published November 26th 2014]

Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy? : A concise exposition of the argument for repurposing drugs in oncology published as an editorial by Future Oncology. [Published January 16th 2015]

Clarithromycin as an anti-cancer agent : A review of the evidence for an anticancer effect of the generic and well-known antibiotic clarithromycin. Includes a discussion of potential combinations with other drugs for treating specific types of cancer. [Published February 24th 2015]

Itraconazole as an anti-cancer agent : Itraconazole is a widely used anti-fungal drug with a long history of use – there is also evidence, outlined in this paper, of potent anticancer activity in a number of different cancers. The paper concludes with an outline of some potential synergistic combinations with other drugs in anticancer protocols for different disease types. [Published April 15th 2015]

Nitroglycerin as an anti-cancer agent : Nitroglycerin is a widely used anti-angina drug with a long history of use – there is also evidence, outlined in this paper, of potent activity against hypoxia and other pathways of interest in cancer treatment. The paper includes an outline of some potential synergistic combinations with other drugs in anticancer protocols for different disease types. [Published August 27th 2015]

Drug repurposing in oncology—patient and health systems opportunities : In most countries, healthcare service budgets are not likely to support the current explosion in the cost of new oncology drugs. Repurposing the large arsenal of approved, non-anticancer drugs is an attractive strategy to offer more-effective options to patients with cancer, and has the substantial advantages of cheaper, faster and safer preclinical and clinical validation protocols… [Published 20 October 2015]

Diclofenac as an anti-cancer agent : Diclofenac is a commonly used non-steroidal anti-inflammatory drug (NSAID) with a long history of clinical use – there is also evidence, outlined in this paper, that it has potential as an anticancer agent. The paper concludes with an outline of some potential synergistic combinations with other drugs in anticancer protocols for different disease types. [Published January 12th 2016]

Propranolol as an anti-cancer agent : Propranolol is a commonly used beta blocker with a long history of clinical use – there is also evidence, outlined in this paper, that it has potential in cancer treatments. In addition to evidence for a direct anti-cancer effect, particularly in angiosarcoma, there is also evidence that it might be effective in a range of cancers when given at the same time as surgery [Published October 12th 2016]